Apyx Medical Corporation announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the use of the Renuvion APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.32 USD | -4.35% | -9.59% | -49.62% |
Apr. 05 | Archon Capital Management Engages with Apyx Medical Corporation | CI |
Apr. 01 | Stavros G. Vizirgianakis Engages in Discussions with Apyx Medical Corporation | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.62% | 47.81M | |
-2.53% | 183B | |
-3.52% | 105B | |
+5.33% | 51.77B | |
+16.43% | 47.29B | |
-1.73% | 40.2B | |
+5.66% | 27.62B | |
-2.01% | 25.51B | |
+9.84% | 24.73B | |
-1.87% | 24.52B |
- Stock Market
- Equities
- APYX Stock
- News Apyx Medical Corporation
- Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion® to Coagulate and Contract Soft Tissues, Including Subcutaneous Tissue, Where Needed